Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease

Withdrawn before enrolling · Phase 4 · Has a placebo group

Conditions studied: Urinary Incontinence, Parkinson's Disease

In brief

The primary purpose of this study is to measure the efficacy of solifenacin succinate (VESIcare) on treating urinary incontinence in Parkinson's disease patients. The secondary objective of this study is to examine the effect of solifenacin succinate (VESIcare) on symptoms of PD and the patient's quality of life.

Key facts

Study ID

NCT00584090

Run by

University of South Florida

People needed

0

Starts

2007-11-01

Last updated by the study team

2012-12-03

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatients with idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnosis Criteria.
• Age 30 years to 80 years.
• Stable dose of antiparkinsonian medication 4 weeks prior to study entry.
• Patients must score 18 or higher on the UPDRS scale and 1.0 to 2.5 on the Modified Hoehn and Yahr scale.
• Women of child-bearing potential must use a reliable method of contraception.
• Must be experiencing symptoms of urinary incontinence (voiding 8 or more times/day or episodes of incontinence 5 or more times per week).
• Patients must have evidence of normal PSA and urodynamic tests within the last 12 months.
• Clearance from the patient's urologist or internist who has examined the patient within the last 12-months.

You may not qualify if…

• Any illness that in the investigator's opinion preclude participation in this study.
• Pregnancy or lactation.
• Concurrent participation in another clinical study.
• Dementia or other psychiatric illness that prevents the patient from giving informed consent (Mini Mental Status Exam score less than 24).
• Legal incapacity or limited legal capacity.
• Presence of severe renal disease (BUN 50% greater than normal).
• Presence of major hepatic impairment.
• Currently taking ketaconazole (anti-fungal) or any CYP3A4 inhibitor.
• Any history of bladder outflow obstruction or gastrointestinal obstructive disorders.
• History of controlled narrow angle glaucoma.

Where it is running

• University of South Florida — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.